帕罗西汀与阿米替林治疗躯体形式障碍对照研究

目的探讨帕罗西汀治疗躯体形式障碍的临床疗效及安全性。方法将42例躯体形式障碍患者随机分为两组各21例,研究组应用帕罗西汀治疗,对照组应用阿米替林治疗,观察8w。于治疗前及治疗第2w、4w、6w、8w末采用症状自评量表评定疗效,副反应量表评定不良反应。结果治疗8w末两组症状自评量表各因子分均较治疗前有极显著下降(P<0.01);治疗2w、4w末对照组焦虑、抑郁因子分较研究组下降显著(P<0.05);4w、6w末研究组躯体化因子较对照组下降显著(P<0.05);8w末两组间各因子分均无显著性差异(P>0.05),两组总体疗效相当;治疗2w、4w、6w、8w末研究组副反应量表总分均显著低于对照组(P<0.01)。结论帕罗西汀治疗躯体形式障碍安全有效,不良反应轻微,患者依从性好。

A control study of paroxetine vs. amitriptyline in the treatment of somatoform disorders

Objective To explore the curative effects and safety of paroxetine in the treatment of somatoform disorders.Methods 42 patients with somatoform disorders were randomly divided into research group(n=21)receiving paroxetine and control group(n=21)doing amitriptyline for 8 weeks.The curative effects were assessewd with the Symptom Checklist(SCL)and adverse effects with the Treatment Emergent Symptom Scale(TESS)before treatment and at the end s of the 2nd,4th,6th and 8th week treatment,respectively.Results At the end of the 8th week,scores of all factors of the SCL of both groups decreased very significantly compared with pre-treatment(P<0.01);at the ends of the 4th and 6th week,scores of anxiety and depression in the control group decreased more significantly than in the research group(P<0.05);those of the somatoform decreased more significantly in the research group than in the control group(P<0.05);at the end of the 8th week,there was no significant difference in inter group comparison(P>0.05)and the curative effects of the two groups were equivalent.Conclusion Paroxetine is safe and effective and has mild side effects and better compliance in the treatment of somatoform disorders.